{"id":32042,"date":"2017-06-10T10:10:49","date_gmt":"2017-06-10T10:10:49","guid":{"rendered":"http:\/\/www.biphoo.com\/bipnews\/?p=32042"},"modified":"2017-06-10T10:10:49","modified_gmt":"2017-06-10T10:10:49","slug":"johnson-johnson-expects-complete-actelion-purchase-june-16","status":"publish","type":"post","link":"https:\/\/www.biphoo.com\/bipnews\/business\/johnson-johnson-expects-complete-actelion-purchase-june-16.html","title":{"rendered":"Johnson &amp; Johnson expects to complete Actelion purchase on June 16"},"content":{"rendered":"<h2 style=\"text-align: justify\">\n\t<span style=\"font-size:22px\"><strong><span style=\"color:#000000\"><span style=\"font-family:arial,helvetica,sans-serif\">Johnson &amp; Johnson expects to complete Actelion purchase on June 16<\/span><\/span><\/strong><\/span><br \/>\n<\/h2>\n<p style=\"text-align: justify\">\n\t<span style=\"font-size:18px\"><span style=\"color:#000000\"><span style=\"font-family:arial,helvetica,sans-serif\">Johnson &amp; Johnson (JNJ.N) said the approval of its proposed acquisition of Swiss biotech firm Actelion (ATLN.S) by the European Commission on Friday meant all regulatory approvals required to complete the $30 billion deal had now been received.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify\">\n\t<span style=\"font-size:18px\"><span style=\"color:#000000\"><span style=\"font-family:arial,helvetica,sans-serif\">The U.S. company said it expected settlement of the all-cash public tender offer by its Swiss subsidiary, Janssen Holding, on June 16.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify\">\n\t<span style=\"font-size:18px\"><span style=\"color:#000000\"><span style=\"font-family:arial,helvetica,sans-serif\">EU antitrust regulators on Friday approved Johnson &amp; Johnson&#039;s planned purchase of Actelion subject to conditions intended to ensure clinical development of insomnia drugs were unaffected.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify\">\n\t<span style=\"font-size:18px\"><span style=\"color:#000000\"><span style=\"font-family:arial,helvetica,sans-serif\">Separately, Actelion said on Friday it had published the prospectus relating to the listing of shares in Idorsia, the spin-off company which will be led by current Actelion Chief Executive Jean-Paul Clozel.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify\">\n\t<span style=\"font-size:18px\"><span style=\"color:#000000\"><span style=\"font-family:arial,helvetica,sans-serif\">Under the agreement all Actelion shareholders will receive one Idorsia share for each Actelion share held on June 13, 2017 with the new company expected to start trading on the Swiss exchange on June 16.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify\">\n\t<span style=\"font-size:18px\"><span style=\"color:#000000\"><span style=\"font-family:arial,helvetica,sans-serif\">Idorsia will specialize in the discovery and development of small molecules in multiple therapeutic areas including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases, the company said.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify\">\n\t<span style=\"font-size:8px\"><span style=\"color:#000000\"><span style=\"font-family:arial,helvetica,sans-serif\">Source:-&nbsp;http:\/\/www.reuters.com\/article\/us-actelion-m-a-johnson-johnson-eu-idUSKBN1901MU<\/span><\/span><\/span><\/p>\n<div class=\"fb-background-color\">\n\t\t\t  <div \n\t\t\t  \tclass = \"fb-comments\" \n\t\t\t  \tdata-href = \"https:\/\/www.biphoo.com\/bipnews\/business\/johnson-johnson-expects-complete-actelion-purchase-june-16.html\"\n\t\t\t  \tdata-numposts = \"10\"\n\t\t\t  \tdata-lazy = \"true\"\n\t\t\t\tdata-colorscheme = \"light\"\n\t\t\t\tdata-order-by = \"social\"\n\t\t\t\tdata-mobile=true>\n\t\t\t  <\/div><\/div>\n\t\t  <style>\n\t\t    .fb-background-color {\n\t\t\t\tbackground: #ffffff !important;\n\t\t\t}\n\t\t\t.fb_iframe_widget_fluid_desktop iframe {\n\t\t\t    width: 630px !important;\n\t\t\t}\n\t\t  <\/style>\n\t\t  ","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson expects to complete Actelion purchase on June 16 Johnson &amp; Johnson (JNJ.N) said the approval of its proposed acquisition of Swiss biotech firm Actelion (ATLN.S) by the European Commission on Friday meant all regulatory approvals required to complete the $30 billion deal had now been received. The [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":32043,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[19805],"class_list":["post-32042","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-johnson-johnson-expects-to-complete-actelion-purchase-on-june-16"],"_links":{"self":[{"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/posts\/32042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/comments?post=32042"}],"version-history":[{"count":0,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/posts\/32042\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/media\/32043"}],"wp:attachment":[{"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/media?parent=32042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/categories?post=32042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/tags?post=32042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}